Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: Akgün, Katja, Behrens, Johanna, Schriefer, Dirk, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696175/
https://www.ncbi.nlm.nih.gov/pubmed/36430240
http://dx.doi.org/10.3390/ijms232213759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696175/
https://www.ncbi.nlm.nih.gov/pubmed/36430240
http://dx.doi.org/10.3390/ijms232213759

Ejemplares similares